| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Alpelisib plus fulvestrant for PIK3CA-mutated breast cancer
|
Stirrups, Robert
|
|
2019
|
20 |
7 |
p. e347
|
artikel
|
| 2 |
American Pain Society forced to close due to opioid scandal
|
Gourd, Elizabeth
|
|
2019
|
20 |
7 |
p. e350
|
artikel
|
| 3 |
2019 ASCO Annual Meeting
|
del Pozo Martín, Yaiza
|
|
2019
|
20 |
7 |
p. 909-910
|
artikel
|
| 4 |
Atezolizumab in combination with carboplatin plus nab-paclitaxel chemotherapy compared with chemotherapy alone as first-line treatment for metastatic non-squamous non-small-cell lung cancer (IMpower130): a multicentre, randomised, open-label, phase 3 trial
|
West, Howard
|
|
2019
|
20 |
7 |
p. 924-937
|
artikel
|
| 5 |
Australia's election could bring down cancer costs for patients
|
McCall, Chris
|
|
2019
|
20 |
7 |
p. 907-908
|
artikel
|
| 6 |
Cediranib for alveolar soft part sarcoma: a randomised study in relation to clinical practice
|
Pasquali, Sandro
|
|
2019
|
20 |
7 |
p. 901-903
|
artikel
|
| 7 |
Cediranib in patients with alveolar soft-part sarcoma (CASPS): a double-blind, placebo-controlled, randomised, phase 2 trial
|
Judson, Ian
|
|
2019
|
20 |
7 |
p. 1023-1034
|
artikel
|
| 8 |
Changing frameworks in treatment sequencing of triple-negative and HER2-positive, early-stage breast cancers
|
Pusztai, Lajos
|
|
2019
|
20 |
7 |
p. e390-e396
|
artikel
|
| 9 |
Combined treatment for locally advanced pancreatic cancer
|
Das, Manjulika
|
|
2019
|
20 |
7 |
p. e351
|
artikel
|
| 10 |
Combined treatment for multiple myeloma
|
Das, Manjulika
|
|
2019
|
20 |
7 |
p. e349
|
artikel
|
| 11 |
Comparison of the accuracy of human readers versus machine-learning algorithms for pigmented skin lesion classification: an open, web-based, international, diagnostic study
|
Tschandl, Philipp
|
|
2019
|
20 |
7 |
p. 938-947
|
artikel
|
| 12 |
Correction to Lancet Oncol 2019; 20: 795–805
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 13 |
Correction to Lancet Oncol 2014; 15: 1503–12
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 14 |
Correction to Lancet Oncol 2019; 20: 986–99
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 15 |
Correction to Lancet Oncol 2019; 20: 765
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 16 |
Correction to Lancet Oncol 2019; 20: 769–80
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 17 |
Correction to Lancet Oncol 2019; 20: e302–12
|
|
|
2019
|
20 |
7 |
p. e346
|
artikel
|
| 18 |
Gaps in US laws leave some vulnerable to workplace discrimination
|
Furlow, Bryant
|
|
2019
|
20 |
7 |
p. 908-909
|
artikel
|
| 19 |
Global childhood cancer survival estimates and priority-setting: a simulation-based analysis
|
Ward, Zachary J
|
|
2019
|
20 |
7 |
p. 972-983
|
artikel
|
| 20 |
GM1 for taxane-induced neuropathy in breast cancer
|
Das, Manjulika
|
|
2019
|
20 |
7 |
p. e348
|
artikel
|
| 21 |
How do you take your coffee?
|
Sissung, Tristan M
|
|
2019
|
20 |
7 |
p. 913-914
|
artikel
|
| 22 |
Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial
|
Rozeman, Elisa A
|
|
2019
|
20 |
7 |
p. 948-960
|
artikel
|
| 23 |
Latest developments in molecular tracers for fluorescence image-guided cancer surgery
|
Hernot, Sophie
|
|
2019
|
20 |
7 |
p. e354-e367
|
artikel
|
| 24 |
Leptomeningeal metastasis of classical Hodgkin lymphoma in a patient with malignant posterior reversible encephalopathy syndrome
|
Kim, David Dongkyung
|
|
2019
|
20 |
7 |
p. e397
|
artikel
|
| 25 |
Machine versus man in skin cancer diagnosis
|
Massi, Daniela
|
|
2019
|
20 |
7 |
p. 891-892
|
artikel
|
| 26 |
NEJ026 trial: progression-free survival benefit is not enough
|
Liang, Fei
|
|
2019
|
20 |
7 |
p. e344
|
artikel
|
| 27 |
NEJ026 trial: progression-free survival benefit is not enough – Author's reply
|
Maemondo, Makoto
|
|
2019
|
20 |
7 |
p. e345
|
artikel
|
| 28 |
Neoadjuvant dabrafenib combined with trametinib for resectable, stage IIIB–C, BRAF V600 mutation-positive melanoma (NeoCombi): a single-arm, open-label, single-centre, phase 2 trial
|
Long, Georgina V
|
|
2019
|
20 |
7 |
p. 961-971
|
artikel
|
| 29 |
Neoadjuvant systemic therapy in melanoma: recommendations of the International Neoadjuvant Melanoma Consortium
|
Amaria, Rodabe N
|
|
2019
|
20 |
7 |
p. e378-e389
|
artikel
|
| 30 |
Neoadjuvant therapy for melanoma: is it ready for prime time?
|
Helmink, Beth
|
|
2019
|
20 |
7 |
p. 892-894
|
artikel
|
| 31 |
New radiotracer shows impressive diagnostic potential
|
Gourd, Elizabeth
|
|
2019
|
20 |
7 |
p. e353
|
artikel
|
| 32 |
NICE guidance on enzalutamide for non-metastatic, hormone-relapsed prostate cancer
|
Brooke, Adam
|
|
2019
|
20 |
7 |
p. 906-907
|
artikel
|
| 33 |
NICE guidance on nivolumab with ipilimumab for untreated advanced renal cell carcinoma
|
Adler, Amanda I
|
|
2019
|
20 |
7 |
p. 904-905
|
artikel
|
| 34 |
Night shift work and breast cancer
|
Burki, Talha Khan
|
|
2019
|
20 |
7 |
p. e352
|
artikel
|
| 35 |
Not old, just older: considering age in cancer care
|
The Lancet Oncology,
|
|
2019
|
20 |
7 |
p. 887
|
artikel
|
| 36 |
Oral targeted agent versus chemotherapy in acute myeloid leukaemia
|
Röllig, Christoph
|
|
2019
|
20 |
7 |
p. 896-898
|
artikel
|
| 37 |
Polatuzumab vedotin in combination with immunochemotherapy in patients with previously untreated diffuse large B-cell lymphoma: an open-label, non-randomised, phase 1b–2 study
|
Tilly, Hervé
|
|
2019
|
20 |
7 |
p. 998-1010
|
artikel
|
| 38 |
Pressurised intraperitoneal aerosol chemotherapy: rationale, evidence, and potential indications
|
Alyami, Mohammad
|
|
2019
|
20 |
7 |
p. e368-e377
|
artikel
|
| 39 |
Quantifying survival disparities among children diagnosed with cancer on a global scale
|
Lupo, Philip J
|
|
2019
|
20 |
7 |
p. 894-896
|
artikel
|
| 40 |
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|
Cortes, Jorge E
|
|
2019
|
20 |
7 |
p. 984-997
|
artikel
|
| 41 |
Scale-up of radiotherapy for cervical cancer
|
Mahantshetty, Umesh M
|
|
2019
|
20 |
7 |
p. 888-889
|
artikel
|
| 42 |
Scale-up of radiotherapy for cervical cancer in the era of human papillomavirus vaccination in low-income and middle-income countries: a model-based analysis of need and economic impact
|
Rodin, Danielle
|
|
2019
|
20 |
7 |
p. 915-923
|
artikel
|
| 43 |
Selumetinib in paediatric low-grade glioma: a new era?
|
Bouffet, Eric
|
|
2019
|
20 |
7 |
p. 900-901
|
artikel
|
| 44 |
Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial
|
Fangusaro, Jason
|
|
2019
|
20 |
7 |
p. 1011-1022
|
artikel
|
| 45 |
Targeted therapies make room, anti-CD79b agents are coming
|
Ferreri, Andrés J M
|
|
2019
|
20 |
7 |
p. 898-900
|
artikel
|
| 46 |
The second wave of checkpoint inhibitors with chemotherapy for advanced non-small-cell lung cancer
|
Li, Yangqiu
|
|
2019
|
20 |
7 |
p. 889-891
|
artikel
|
| 47 |
Vlogging at the end of life
|
Sánchez-Querubín, Natalia
|
|
2019
|
20 |
7 |
p. 911-912
|
artikel
|
Tijdschrift beschrijving